Pharmaceuticals

Global Autoimmune Gastrointestinal Dysmotility Market Analysis 2025–2029: Opportunities for Strategic Growth

November 10, 2025 by Marketing Posting

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

How Much Larger Is The Autoimmune Gastrointestinal Dysmotility Market Expected To Become By 2029 Compared With Its 2025 Level?

The autoimmune gastrointestinal dysmotility market size has shown consistent growth over recent years. It is anticipated to increase from $1.73 billion in 2024 to $1.82 billion in 2025, achieving a compound annual growth rate (CAGR) of 5.0%. The expansion observed in prior periods can be attributed to several factors including heightened unawareness of rare diseases, the prevalence of underdeveloped diagnostic approaches, an increase in instances of misdiagnosis with other gastrointestinal disorders, the scarcity of targeted therapeutic options, and ongoing setbacks in research development.

The autoimmune gastrointestinal dysmotility market is poised for significant expansion in the coming years, with projections indicating a rise to $2.37 billion by 2029, reflecting a compound annual growth rate (CAGR) of 6.9%. This anticipated growth throughout the forecast period can be attributed to factors such as the increasing incidence of autoimmune diseases, improvements in diagnostic techniques, elevated healthcare expenditure, the establishment of more rare disease registries, and enhanced education for clinicians. Prominent trends expected to influence the market in the forecast period include technological breakthroughs in diagnostics, new innovations in immunotherapy, the advancement of neurogastroenterology research, extensive research and development into motility modulators, and the implementation of personalized treatment approaches.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24160&type=smp

Which Drivers Are Supporting Growth Of The Autoimmune Gastrointestinal Dysmotility Market?

The increasing occurrence of autoimmune conditions is anticipated to fuel the expansion of the autoimmune gastrointestinal dysmotility market moving ahead. Autoimmune diseases are illnesses where the body’s immune system erroneously targets its own healthy cells, tissues, or organs, rather than defending against infections and external entities. The growing incidence of autoimmune disorders mainly stems from a blend of genetic predisposition and environmental factors, which collectively interfere with immune system regulation, thereby elevating the chance of the body assaulting its own tissues. Autoimmune gastrointestinal dysmotility aids in detecting and addressing underlying autoimmune conditions by uncovering immune-related harm to the enteric nervous system, thus connecting gastrointestinal manifestations with widespread autoimmune activity. As an illustration, in November 2024, a survey conducted by Versorgungsatlas.de, an organization based in Germany, among 73,241,305 individuals in 2022, reported that approximately 6,304,340 received a diagnosis of at least one autoimmune disease, yielding a crude prevalence rate of 8.61. Consequently, the increasing prevalence of autoimmune disorders is propelling the expansion of the autoimmune gastrointestinal dysmotility market.

What Are The Segment Types Shaping The Autoimmune Gastrointestinal Dysmotility Market?

The autoimmune gastrointestinal dysmotility market covered in this report is segmented –

1) By Treatment Type: Medications, Surgical Interventions, Dietary Management, Physical Therapy

2) By Drug Class: Prokinetic Agents, Anti-Inflammatory Drugs, Immunosuppressive Drugs, Antibiotics

3) By Disease Type: Gastroparesis, Chronic Intestinal Pseudo-Obstruction (Cipo), Functional Dyspepsia, Irritable Bowel Syndrome (Ibs), Celiac Disease

4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacies, Other Distribution Channels

5) By End User: Hospitals, Clinics, Home Care Settings, Research Institutions

Subsegments:

1) By Medications: Immunosuppressants, Corticosteroids, Prokinetic Agents, Antiemetics, Antispasmodics, Antibiotics

2) By Surgical Interventions: Gastrostomy, Jejunostomy, Colostomy, Ileostomy, Pyloroplasty, Colectomy

3) By Dietary Management: Enteral Nutrition, Parenteral Nutrition, Gluten-Free Diet, Elemental Diet, Small Frequent Meals

4) By Physical Therapy: Pelvic Floor Therapy, Abdominal Massage Therapy, Neuromuscular Electrical Stimulation (NMES), Biofeedback Therapy, Respiratory Muscle Training, Postural Training

What Long-Term Trends Will Shape The Future Growth Of The Autoimmune Gastrointestinal Dysmotility Industry?

Leading firms within the autoimmune gastrointestinal dysmotility market are prioritizing strategic alliances to deliver digital therapeutic interventions for handling autoimmune gastrointestinal dysmotility conditions. These collaborative strategies improve autoimmune gastrointestinal dysmotility care through integrated, virtual-first healthcare supported by multidisciplinary teams, which in turn enhances symptom control, broadens access to treatment, and optimizes cost-effectiveness. An example of this trend is seen in March 2022, when Solera Health, a US-based digital health entity, formed a partnership with Oshi Health, a US-based virtual gastrointestinal care provider, and Vivante Health, another US-based digital health company. This joint effort aims to deliver advanced digital therapeutic solutions designed to aid in the ongoing management and treatment of autoimmune gastrointestinal dysmotility. The overarching goal of this collaboration is to expand patient access to specialized medical attention and boost the comprehensive effectiveness of treatment for those living with gastrointestinal disorders.

Which Leading Players Are Enhancing Their Autoimmune Gastrointestinal Dysmotility Market Presence Worldwide?

Major companies operating in the autoimmune gastrointestinal dysmotility market are AbbVie Inc., GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Chugai Pharmaceutical Co. Ltd., Zeria Pharmaceutical Co. Ltd., Ironwood Pharmaceuticals Inc., Vanda Pharmaceuticals Inc., Dr. Falk Pharma GmbH, Rose Pharma LLC, Parvus Therapeutics Inc., CinDome Pharma Inc., Neurogastrx Inc., Renexxion LLC, ISOThrive Inc., Ambrose Healthcare Inc., AnTolRx Inc., Enteralia Bioscience S.r.l., Immunic Inc., Mozart Therapeutics Inc.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/autoimmune-gastrointestinal-dysmotility-global-market-report

Which Region Shows The Highest Potential For Future Expansion In The Autoimmune Gastrointestinal Dysmotility Market?

North America was the largest region in the autoimmune gastrointestinal dysmotility market in 2024. The regions covered in the autoimmune gastrointestinal dysmotility market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Autoimmune Gastrointestinal Dysmotility Market Report:

https://www.thebusinessresearchcompany.com/customise?id=24160&type=smp

Browse Through More Reports Similar to the Global Autoimmune Gastrointestinal Dysmotility Market 2025, By The Business Research Company

Autoimmune Disease Diagnosis Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/autoimmune-disease-diagnosis-global-market-report

Granulocyte Colony Stimulating Factors Market 2025

https://www.thebusinessresearchcompany.com/report/granulocyte-colony-stimulating-factors-market

Autoimmune Disease Diagnosis Market 2025

https://www.thebusinessresearchcompany.com/report/autoimmune-disease-diagnosis-market

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795